Vericiguat study in heart failure patients after a heart attack
Studies vericiguat added to usual care in adults with heart failure after a heart attack.
Plain-language title generated from the registry record
Registry title: Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
Key facts
- Where
- Jinan, ChinaSee the 3 sites
Where in China
- Central Hospital Affiliated to Shandong First Medical UniversityJinan, ChinaNo longer taking part
- Qilu Hospital of Shandong UniversityJinan, ChinaNo longer taking part
- The First Affiliated Hospital of Shandong First Medical University/Shandong Province Qianfoshan HospitalJinan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT06717204
- Record updated
- 4 December 2024
- Original description
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.Read full original descriptionShow less
Vericiguat for Ventricular Remodeling in Patients With Heart Failure With Reduced Ejection Fraction After Myocardial Infarction
The effects of vericiguat on cardiac remodeling in patients with chronic stable heart failure after myocardial infarction have not been reported. This project aims to clarify the efficacy and safety of vericiguat in patients with chronic heart failure after myocardial infarction. Patients with chronic stable heart failure with reduced ejection fraction after myocardial infarction in the electronic medical records of Qilu Hospital of Shandong University will be selected and divided into two groups: the treatment group received vericiguat in addition to conventional treatment and the control group received conventional treatment only. After 12-month treatment, the effects of vericiguat on cardiac remodeling and function and cardiovascular adverse events will be evaluated. The results are helpful to provide a new treatment strategy for chronic heart failure after myocardial infarction.
Inclusion: The history of acute myocardial infarction exceeds 3 months; Symptoms and signs of heart failure have been stable for more than one month; 18 years old or more; NYHA cardiac function classified as grade II~IV; LVEF≤40%；; NT-proBNP≥450pg/ml；; All subjects or their guardians must sign the subject consent before entering the trial.
Exclusion: Patients with the following diseases: nonischemic cardiomyopathy; valvular heart disease; congenital heart disease; obstruction of left ventricular outflow tract; severe decompensated heart failure; active myocarditis or pericardial disease; end-stage liver and kidney diseases; malignant tumor; Mechanical complications of myocardial infarction; Unable to obtain primary outcome data.